Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Eastern Cooperative Oncology Group
Radboud University Medical Center
Queensland Centre for Gynaecological Cancer
Brigham and Women's Hospital
M.D. Anderson Cancer Center
Queensland Centre for Gynaecological Cancer
University of Utah
St. Antonius Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
UNC Lineberger Comprehensive Cancer Center
St. Antonius Hospital
First Affiliated Hospital of Zhejiang University
Copernicus Memorial Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shanghai Gynecologic Oncology Group
NRG Oncology
University Hospital, Montpellier
Qilu Pharmaceutical Co., Ltd.
Gaziosmanpasa Research and Education Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
MegaPro Biomedical Co. Ltd.
Instituto do Cancer do Estado de São Paulo
Karolinska Institutet
Canisius-Wilhelmina Hospital
Jewish General Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
St. Borbala Hospital
Huashan Hospital
University Hospital, Ghent
AC Camargo Cancer Center
RDO Pharm.
Second Affiliated Hospital of Xi'an Jiaotong University
Peking University Cancer Hospital & Institute
University of Leeds
Haraldsplass Deaconess Hospital
University Medical Center Groningen
Umeå University
Sahlgrenska University Hospital
Shanghai Zhongshan Hospital
University of Texas Southwestern Medical Center
Dana-Farber Cancer Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dana-Farber Cancer Institute
Uppsala University Hospital
Fujian Medical University